//Newsletter July 2017

Newsletter July 2017


NEWSWORTHY
Indee Labs closes $1.3M

Indee Labs recently closed a $1.3M angel round and demonstrated functional modification of human primary T-cells with high efficiency (30 to 60%), cell viability (>85%) and recovery (>90%) without T-cell exhaustion or activation. They've also signed its first customer.
UPCOMING EVENTS
Lunch Seminar and Office Hours: July 18, 12:00 - 3:30 PM

12:00 - 1:00 PM: Amgen Innovator Series
Whole Biome: A Microbiome Company
Colleen Cutcliffe, PhD
CEO and Co-Founder, Whole Biome

RSVP

Whole Biome has developed a discovery platform which obtains high resolution microbial and microbiome data, and utilizes data analytics and machine learning to identify key relevant factors. This talk will highlight the fundamentals of the microbiome space and Whole Biome's unique path and products.
Colleen Cutcliffe is the CEO and Co-Founder of Whole Biome Inc. Colleen has over 15 years of experience managing teams in biotech, pharma and academia. Before starting Whole Biome, Colleen served as the Senior Manager of Biology at Pacific Biosciences, which is where she met her two co-founders. Prior to that, Colleen was a Scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral research at Northwestern's Children's Memorial Hospital, received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and received her B.A. in Biochemistry from Wellesley College. Colleen currently resides in Menlo Park, California with her husband, 2 kids, 2 dogs, 2 birds and 2 hamsters...all contributing to a diverse microbiome!
 
1:00 - 3:30 PM: Amgen Office Hours
Samantha Palmer, PhD
Senior Licensing Manager, Amgen

To apply for Office Hours, please contact Linda Eng.

Samantha Palmer Ph.D. joined Amgen in 2015 and is the Senior Licensing Manager for Inflammation. She has an extensive background in immunology and microbiology and leads the Inflammation product search and evaluation efforts for Amgen business development covering Rheumatology, Dermatology, Respiratory and Specialty Gastro-Intestinal diseases.
Office Hours: July 28, 1:00 - 3:00 PM
Gregory S. Naeve, PhD
Head of External R&D, Pfizer

To apply for Office Hours, please contact Linda Eng.
Dr. Naeve is currently the Head of External R&D for Pfizer's Cancer Immunotherapy programs. He is also head of global scouting in the Northwest region of North America. In this role Greg is responsible for liaising with Pfizer Scientists to identify and institute strategic partnerships that address internal technology and pipeline needs. Prior to Pfizer he worked as a venture capitalist with the San Francisco-based life science venture fund, The Column Group, a firm focused on creating biotechnology companies to develop novel therapeutics and technologies. Prior to that he was the President and Chief Scientific Officer of Parallax Biosystems, a company he co-founded to develop a molecular detection platform with applications in pre-clinical drug discovery and diagnostics. Before Parallax he held positions at Neurocrine Biosciences and Amgen working to develop new therapies for neurodegenerative disorders. He received his Ph.D. in Biochemistry from the University of Southern California.
OUR PARTNERS
2019-01-14T12:59:16+00:00July 1st, 2017|Newsletters 2017|